These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 2182442)

  • 1. Improved prognosis for childhood acute lymphocytic leukemia with very high white blood cell count (greater than 100/nl) with rotation of non-cross-resistant drug combinations.
    Janka-Schaub GE; Goebel U; Graubner U; Haas RJ; Juergens H; Spaar HJ; Winkler K
    Haematol Blood Transfus; 1990; 33():489-93. PubMed ID: 2182442
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of early intensive reinduction therapy on event-free survival in children with low-risk acute lymphoblastic leukemia.
    Henze G; Fengler R; Reiter A; Ritter J; Riehm H
    Haematol Blood Transfus; 1990; 33():483-8. PubMed ID: 2182441
    [No Abstract]   [Full Text] [Related]  

  • 3. Favorable outcome for children and adolescents with T-cell lymphoblastic lymphoma with an intensive ALL-type therapy without local radiotherapy.
    Grenzebach J; Schrappe M; Ludwig WD; Parwaresch R; Zimmermann M; Gadner H; Riehm H; Reiter A;
    Ann Hematol; 2001; 80 Suppl 3():B73-6. PubMed ID: 11757713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of IKZF1 deletions in association with vincristine-dexamethasone pulses during maintenance treatment of childhood acute lymphoblastic leukemia on trial ALL-BFM 95.
    Hinze L; Möricke A; Zimmermann M; Junk S; Cario G; Dagdan E; Kratz CP; Conter V; Schrappe M; Stanulla M
    Leukemia; 2017 Aug; 31(8):1840-1842. PubMed ID: 28529312
    [No Abstract]   [Full Text] [Related]  

  • 5. Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica.
    Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi A; Miniero R; Di Tullio MT; Lo Nigro L; Pession A; Rondelli R; Messina C; Santoro N; Mori PG; De Rossi G; Tamaro P; Silvestri D; Biondi A; Basso G; Masera G
    Haematologica; 1998 Sep; 83(9):791-9. PubMed ID: 9825576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906.
    Bowman WP; Larsen EL; Devidas M; Linda SB; Blach L; Carroll AJ; Carroll WL; Pullen DJ; Shuster J; Willman CL; Winick N; Camitta BM; Hunger SP; Borowitz MJ
    Pediatr Blood Cancer; 2011 Oct; 57(4):569-77. PubMed ID: 21360654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.
    Larson RA; Dodge RK; Burns CP; Lee EJ; Stone RM; Schulman P; Duggan D; Davey FR; Sobol RE; Frankel SR
    Blood; 1995 Apr; 85(8):2025-37. PubMed ID: 7718875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of prognostic factors on the course of acute lymphoblastic leukemia in children].
    Rokicka-Milewska R; Derulska D; Lewicki Z
    Pediatr Pol; 1988 Nov; 63(11):703-15. PubMed ID: 3253657
    [No Abstract]   [Full Text] [Related]  

  • 9. Successful treatment of acute lymphoblastic leukemia in a child with cystic fibrosis.
    Gururangan S; Horner M; Rodman JH; Marina NM
    Med Pediatr Oncol; 1994; 22(6):414-6. PubMed ID: 8152404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Sancho JM; Ribera JM; Xicoy B; Morgades M; Oriol A; Tormo M; del Potro E; Debén G; Abella E; Bethencourt C; Ortín X; Brunet S; Ortega-Rivas F; Novo A; López R; Hernández-Rivas JM; Sanz MA; Feliu E;
    Eur J Haematol; 2007 Feb; 78(2):102-10. PubMed ID: 17087744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Follow-up of the first two successive German multicentre trials for adult ALL (01/81 and 02/84). German Adult ALL Study Group.
    Hoelzer D; Thiel E; Ludwig WD; Löffler H; Büchner T; Freund M; Heil G; Hiddemann W; Maschmeyer G; Völkers B
    Leukemia; 1993 Aug; 7 Suppl 2():S130-4. PubMed ID: 8361217
    [No Abstract]   [Full Text] [Related]  

  • 12. The role of radiation therapy in the treatment of acute lymphoblastic leukemia with lymphomatous presentation: a report from the Childrens Cancer Group.
    Cherlow JM; Steinherz PG; Sather HN; Gaynon PS; Grossman NJ; Kersey JH; Johnstone HS; Breneman JC; Trigg ME; Hammond GD
    Int J Radiat Oncol Biol Phys; 1993 Dec; 27(5):1001-9. PubMed ID: 8262820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Investigations in the use of mogramostime (GM-CSF) in patients with acute leukemia].
    Paśnicki M
    Wiad Lek; 1995; 48(1-12):194-7. PubMed ID: 9638239
    [No Abstract]   [Full Text] [Related]  

  • 14. A classification based on T cell selection-related phenotypes identifies a subgroup of childhood T-ALL with favorable outcome in the COALL studies.
    Niehues T; Kapaun P; Harms DO; Burdach S; Kramm C; Körholz D; Janka-Schaub G; Göbel U
    Leukemia; 1999 Apr; 13(4):614-7. PubMed ID: 10214870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial.
    Attarbaschi A; Mann G; Zimmermann M; Bader P; Barisone E; Basso G; Biondi A; Cario G; Cazzaniga G; Colombini A; Flotho C; Kuhlen M; Lang P; Lauten M; Linderkamp C; Locatelli F; Lo Nigro L; Möricke A; Niggli F; Panzer-Grümayer R; Parasole R; Peters C; Caterina Putti M; Rizzari C; Suttorp M; Valsecchi MG; Conter V; Schrappe M;
    Leukemia; 2020 Jun; 34(6):1694-1700. PubMed ID: 31806872
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of relapsed acute lymphocytic leukemia in adults.
    Freund M; De Boben M; Diedrich H; Ganser A; Heil G; Heyll A; Henke M; Hiddemann W; Knauf U; Koch P
    Haematol Blood Transfus; 1990; 33():432-6. PubMed ID: 2182434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poor outcome of intensive chemotherapy for adult acute lymphoblastic leukemia: a possible dose effect.
    Chiu EK; Chan LC; Liang R; Lie A; Kwong YL; Todd D; Chan TK
    Leukemia; 1994 Sep; 8(9):1469-73. PubMed ID: 8090027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial of induction therapy (daunorubicin, vincristine, prednisone versus daunorubicin, vincristine, prednisone, cytarabine and 6-thioguanine) in adult acute lymphoblastic leukemia with long-term follow-up: an Eastern Cooperative Oncology Group Study (E3486).
    Wiernik PH; Cassileth PA; Leong T; Hoagland HC; Bennett JM; Paietta E; Oken MM;
    Leuk Lymphoma; 2003 Sep; 44(9):1515-21. PubMed ID: 14565653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG).
    van der Does-van den Berg A; van Wering ER; Suciu S; Solbu G; van 't Veer MB; Rammeloo JA; de Koning J; van Zanen GE
    Am J Pediatr Hematol Oncol; 1989; 11(2):125-33. PubMed ID: 2665546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Initial response to therapy as an important prognostic factor in acute lymphoblastic leukemia in childhood. COALL study group].
    Janka-Schaub GE; Stührk H; Kortüm B; Graubner U; Jürgens H; Spaar HJ; Schöck V; Dohrn B; Bahr R; Winkler K
    Klin Padiatr; 1991; 203(4):231-5. PubMed ID: 1942930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.